Trial Profile
An exploratory open-label PET-observer-blinded pilot study to evaluate the effect of 3 and 12 months treatment with Aliskeren-based versus amlodipin-based antihypertensive treatment in patients with a small abdominal aortic aneurysm and mild to moderate hypertension on aneurysmal FDG-uptake as measured with FDG PET.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide
- Indications Hypertension
- Focus Pharmacodynamics
- Acronyms PISA
- 08 Dec 2014 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
- 31 Aug 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01425242).
- 26 Aug 2011 Planned end date changed from 14 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.